Targeting FGF23 to Ameliorate Anemia in Chronic Kidney Disease
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27198618 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Karen Cecilia Valdés-Díaz und 16 weiteren Autor:innen. Beteiligte Einrichtung: Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University Hospital Reina Sofia, University of Cordoba, 14004 Cordoba, Spain. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Renal Insufficiency, Chronic, Anemia. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Consejería de Salud y Consumo, European Funds.
Abstract (Originalsprache)
The progression of chronic kidney disease (CKD) entails the development of complications, such as anemia and disturbances in mineral homeostasis, among others, and both of them have been shown to be closely related. In fact, high phosphorus (P) and excessive production of fibroblast growth factor 23 (FGF23) are hallmarks of the mineral alterations found in CKD, both of which have been associated with the development of anemia. The objective of this study was to evaluate whether the modulation of P load may impact the severity of CKD-related anemia as well as to separate the effects of FGF23 from those of P by the administration of an AntiFGF23 antibody while also investigating the involvement of hypoxia-inducible factor (HIF) signaling in these actions. To address this objective, we used a CKD model based on 5/6 nephrectomy (Nx). In a first experiment, CKD rats received diets with 0.2, 0.6, or 1.2% of P for 4 weeks. In a second study, Nx rats fed a 1.2% P diet were treated with an AntiFGF23 antibody for the same period. In an additional experiment, the effect of the exogenous administration of FGF23 and AntiFGF23 was evaluated. In all the experiments, we analyzed the hematological status, parameters of renal function and mineral metabolism, and HIF signaling. In CKD, the increase in P load was associated with an expected progressive elevation in FGF23 and an aggravation of anemia. In a situation of uremia with high P load, the neutralization of FGF23 restored hematological alterations while producing a significant inhibition in renal HIF1Alpha. In the absence of renal damage, the administration of recombinant FGF23 produced a decrease in serum iron and reticulocytes without changes in HIF signaling. In conclusion, progressive and concomitant increases in P and FGF23 produce an aggravation of anemia of renal origin. In this setting, the normalization of hematological parameters induced by FGF23 blockade is associated with the inhibition of renal HIF signaling. Thus, the implementation of FGF23-targeting therapies might constitute an additional strategy for the clinical management of CKD-related anemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University Hospital Reina Sofia, University of Cordoba, 14004 Cordoba, Spain.
- Health Results-Oriented Cooperative Research Network RICORS2040 RD24/0004/0004 (Kidney Disease), Institute of Health Carlos III, 28029 Madrid, Spain.
- Nephrology Service, Reina Sofia University Hospital, Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC), University of Cordoba, 14004 Cordoba, Spain.
- Department of Integrated Sciences, Research Center on Natural Resources, Health, and Environment (RENSMA), University of Huelva, 21007 Huelva, Spain.
ORCID-Profile: Karen Cecilia Valdés-Díaz, Raquel María García-Sáez, Daniel Jurado-Montoya, Antonio Rivas-Domínguez, Teresa Obrero, Rafael Serrano-Berzosa, Antonio Canalejo, Mariano Rodríguez, Juan Rafael Muñoz-Castañeda, Alejandro Martín-Malo, María Encarnación Rodríguez-Ortiz
Förderung
- Instituto de Salud Carlos III
- Consejería de Salud y Consumo
- European Funds
- Consejería de Salud de la Junta de Andalucia
- European Uremic Toxin Work Group
Zitieren
APA
Valdés-Díaz, K. C., García-Sáez, R. M., Valle, C., Torralbo-Romero, A. I., Jurado-Montoya, D., Rivas-Domínguez, A., Obrero, T., Jiménez, M. J., Guerrero, F., López-Baltanás, R., Serrano-Berzosa, R., Mendiburu-Quintana, M., Canalejo, A., Rodríguez, M., Muñoz-Castañeda, J. R., Martín-Malo, A., & Rodríguez-Ortiz, M. E. (2026). Targeting FGF23 to Ameliorate Anemia in Chronic Kidney Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27198618
Vancouver
Valdés-Díaz KC, García-Sáez RM, Valle C, Torralbo-Romero AI, Jurado-Montoya D, Rivas-Domínguez A, et al. Targeting FGF23 to Ameliorate Anemia in Chronic Kidney Disease. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27198618
BibTeX
@article{ValdsDaz2026,
author = {Valdés-Díaz, Karen Cecilia and García-Sáez, Raquel María and Valle, Casimiro and Torralbo-Romero, Ana Isabel and Jurado-Montoya, Daniel and Rivas-Domínguez, Antonio and Obrero, Teresa and Jiménez, María José and Guerrero, Fátima and López-Baltanás, Rodrigo and Serrano-Berzosa, Rafael and Mendiburu-Quintana, Miguel and Canalejo, Antonio and Rodríguez, Mariano and Muñoz-Castañeda, Juan Rafael and Martín-Malo, Alejandro and Rodríguez-Ortiz, María Encarnación},
title = {Targeting FGF23 to Ameliorate Anemia in Chronic Kidney Disease},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27198618}
}
EUVIMED